MarketPulse

Agios Pharmaceuticals

3 articles
The Motley FoolThe Motley Fool··Eric Volkman

Agios Pharmaceuticals Surges 13% on Beat Earnings, Expanding Mitapivat Market

Agios Pharmaceuticals surged 13% on strong Q1 earnings, with mitapivat revenue jumping 138% to $20.7M. Company plans supplemental FDA application for sickle cell disease expansion.
AGIOFDA approvalsickle cell disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Agios Pharmaceuticals Eyes Accelerated FDA Approval Path for Mitapivat in Sickle Cell

Agios Pharmaceuticals to report Q1 2026 results April 29 amid FDA accelerated approval pursuit for sickle cell mitapivat and UAE thalassemia approval.
AGIOrare diseasesFDA
The Motley FoolThe Motley Fool··James Brumley

Agios Pharma Soars 21% on FDA Fast-Track Win for Sickle Cell Drug

Agios Pharmaceuticals surges on FDA accelerated approval for mitapivat sickle cell treatment, enabling faster path to full approval despite company's ongoing losses.
AGIObiotechpharmaceutical